الفهرس 
LEFT VENTRICULAR HYPERTROPHY (LVH) AND CARDIAC REMODELINGOnly 14 pages are availabe for public view
 |  | from | 151 |  |  |
| | | from | 151 | | |
Abstract
The aim of this study was to measure serum level of tenascin-C in patients with left ventricular hypertrophy, in order to explore its potential diagnostic utility for cardiac remodeling in those patients.
This study was conducted on 30 patients suffering from LVH due to systemic hypertension; 8 patients suffering from systemic hypertension without LVH and 20 apparently healthy subjects serving as control group. In addition, patients with systemic hypertension together with LVH were subdivided according to the severity of the disease into 2 subgroups; subgroup a (stage 1 hypertension, n=14) & subgroup b (stage 2 hypertension, n=16).
All studied groups were subjected to history taking and clinical examination. Blood samples were collected for determination of lipid profile, and serum TnC. Assay of TnC was carried using Enzyme Linked Immunosorbant Assay (ELISA).
Significant higher levels of TnC were observed in hypertensive patients with LVH when compared to control group.
When ROC curve analysis was applied to asses diagnostic performance of serum TnC in hypertensive patients with LVH versus healthy control group, it revealed a cut-off 1.10 ng/ml, the diagnostic sensitivity was 67%, the diagnostic specificity was 75%, positive predictive value(PPV) 80%, negative predictive value(NPV) 60% and diagnostic efficacy 70%.
In conclusion, Serum TnC levels showed a statistically significant increase in patients with LVH associated with hypertension compared to controls. Serum TnC is a promising diagnostic marker for identifying patients with tissue remodeling in LVH with hypertension. It can also be used as a potential marker to detect beneficial effects of pharmacotherapy with anti remodeling drugs.